tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Legend Biotech Reports Strong Sales for CARVYKTI® in Q2 2025

Story Highlights
Legend Biotech Reports Strong Sales for CARVYKTI® in Q2 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Genscript Biotech ( (HK:1548) ) has shared an update.

Legend Biotech, an associate of Genscript Biotech, announced that its product CARVYKTI® generated approximately $439 million in net trade sales for the quarter ending June 30, 2025. This financial performance is linked to a collaboration with Janssen Biotech, highlighting the product’s market success and potential impact on Genscript’s financial standing and industry positioning.

More about Genscript Biotech

Genscript Biotech Corporation, incorporated in the Cayman Islands, operates in the biotechnology industry. The company is associated with Legend Biotech Corporation, which is involved in the development of pharmaceutical products and is listed on the Nasdaq Global Select Market in the U.S.

Average Trading Volume: 24,957,436

Technical Sentiment Signal: Buy

Current Market Cap: HK$32.93B

Learn more about 1548 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1